Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T_reg cells.

ABSTRACT: Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone¹. However, there remains little consensus on the mechanism(s) of response with this combination². Here we find that a high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients treated with atezolizumab plus tiragolumab but not with atezolizumab alone. Serum sample analysis revealed that macrophage activation is associated with a clinical benefit in patients who received the combination treatment. In mouse tumour models, tiragolumab surrogate antibodies inflamed tumour-associated macrophage

SUBMITTER: Guan X 

PROVIDER: S-EPMC11139643 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature